News #ECTRIMS2016 – Oryzon to Present Positive Preclinical Data on Potential MS Therapy #ECTRIMS2016 – Oryzon to Present Positive Preclinical Data on Potential MS Therapy by Kara Elam | September 14, 2016 Share this article: Share article via email Copy article link Researchers from OryzonĀ will presentĀ efficacy data on the companyās oral epigenetic drugĀ ORY-2001, a potential treatment for multiple sclerosis (MS), at theĀ European Committee for Treatment and Research in Multiple SclerosisĀ (ECTRIMS) congress taking place this week in London. The poster presentation, āLSD1 inhibition, a potential epigenetic therapeutic approach for the treatment of multiple sclerosis,ā is based on findings from an animal model of MS after treatment with ORY-2001. ORY-2001 is a highly selective inhibitor of LSD1 and MAOB. LSD1 is an enzyme able to regulate theĀ expression of many genes important in the onset and progression of neurodegenerative diseases, viral infections, and cancer, among others illnesses. By blocking LSD1 activity, ORY-2001 can modify gene expression, and for this reason is referred to as an epigenetic drug (epigenetics is the study of changes in gene expression). Researchers used a common experimental animal model of MS, the experimental autoimmune encephalomyelitis (EAE)Ā mouse model, and found that treatment with ORY-2001 reduced disease incidence and severity. The findings are the first to show that epigenetic modulation could potentially be a successful treatment option for MS, the company said. “[T]he positive results obtained in different animal models of neurodegenerative and neuroinflammatory disorders suggest that common components controlled by epigenetic mechanisms may contribute to different diseases and suggests a way to explore novel therapies,”Ā Tamara Maes, PhD, co-founder, vice president and chief scientific officer of Oryzon, said in a company press release. Oryzon also announced thatĀ Dr. Xavier Montalban, an MS specialist and member ofĀ ECTRIMSā Executive Committee, has joined its Scientific Advisory Board to assist itĀ in furtherĀ exploring the clinical potential of LSD1 inhibitors, such as ORY-2001, toĀ treat neuroinflammatory disorders like MS. The 32nd ECTRIMS congress runs through Sept. 17 and is consideredĀ the “world’s largest annual international conference devoted to basic and clinical research in MS.” This year’s congress brings together over 8,000 clinical and research professionals in neuroscience and MS, and includes 61 different topic sessions. More than 2,000 abstracts will be presented. Print This Page About the Author Kara Elam Kara Elam is currently working on her Doctorate in Health Policy. She holds Master Degrees in both epidemiology and microbiology. Her research interests include emerging viral diseases, the intersection of human rights and intellectual property rights, and ending violence against women. Tags ECTRIMS2016, epigenetics, neurodegenerative disorders
April 19, 2024 News by Lindsey Shapiro, PhD AAN 2024: Long-term data support early Kesimpta start in relapsing MS
April 18, 2024 Columns by Benjamin Hofmeister Learning how to write a ‘SOAP’ note feels different after an MS diagnosis
April 18, 2024 News by Marisa Wexler, MS AAN 2024: Sustained myelin, nerve cell gains with long-term CNM-Au8